SAVA
NASDAQ · Pharmaceuticals
Cassava Sciences Inc
$1.85
-0.03 (-1.60%)
Financial Highlights (FY 2025)
Revenue
22.84M
Net Income
4.14M
Gross Margin
32.2%
Profit Margin
18.1%
Rev Growth
-6.9%
D/E Ratio
1.35
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 32.2% | 32.2% | 32.2% |
| Operating Margin | 21.8% | 24.1% | 22.1% |
| Profit Margin | 18.1% | 25.2% | 19.3% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 22.84M | 20.47M | 21.96M |
| Gross Profit | 7.36M | 6.60M | 7.08M |
| Operating Income | 4.98M | 4.93M | 4.85M |
| Net Income | 4.14M | 5.17M | 4.25M |
| Gross Margin | 32.2% | 32.2% | 32.2% |
| Operating Margin | 21.8% | 24.1% | 22.1% |
| Profit Margin | 18.1% | 25.2% | 19.3% |
| Rev Growth | -6.9% | +1.2% | +18.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 43.58M | 40.03M | 39.84M |
| Total Equity | 32.33M | 29.33M | 28.67M |
| D/E Ratio | 1.35 | 1.36 | 1.39 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.09M | 5.98M | 7.27M |
| Free Cash Flow | 3.09M | 2.63M | 3.14M |